Morgan Stanley initiated coverage of GSK (GSK) with an Equal Weight rating and 1,450 GBp price target The shares trade at an inexpensive valuation but the company’s mid- to longer-term growth remains challenging, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK price target raised to 1,500 GBp from 1,440 GBp at JPMorgan
- Trump Trade: President advocates to close carried interest tax loophole
- GSK sued by Arizona AG for engaging in ‘deceptive’ practices
- GlaxoSmithKline (GSK) Announces Q2 Dividend: Read On for Important Dates
- GSK Earnings Call: Robust Growth Amidst Challenges